A quantitative LC-MS/MS method for simultaneous determination of deuvortioxetine, vortioxetine and their carboxylic acid metabolite in rat plasma, and its application to a toxicokinetic study

First deuterated drug approved

(2017) Charles Schmidt   NATURE BIOTECHNOLOGY

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease

(2016) et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC–MS/MS: Application to their pharmacokinetic interaction study

(2016) Yi Huang et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

An UPLC–MS/MS method for the quantitation of vortioxetine in rat plasma: Application to a pharmacokinetic study

(2015) Er-min Gu et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Quantitative determination of the antidepressant vortioxetine and its major human metabolite in plasma

(2015) Morten A Kall et al.   Bioanalysis

Depression in Europe: does migrant integration have mental health payoffs? A cross-national comparison of 20 European countries

(2014) Katia Levecque et al.   ETHNICITY & HEALTH

Vortioxetine: First Global Approval

(2013) Andrew Gibb et al.   DRUGS

5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects

(2013) Per Stenkrona et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

(2013) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Kinetic deuterium isotope effects in cytochrome P450 oxidation reactions

(2013) F. Peter Guengerich   JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS

Occupancy of the Serotonin Transporter after Administration of Lu AA21004 and its Relation to Plasma Concentration in Healthy Subjects

(2011) Johan Areberg et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

(2011) Enric Alvarez et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

(2011) Benny Bang-Andersen et al.   JOURNAL OF MEDICINAL CHEMISTRY